"Aetna's underperformance year-to-date is the main driver of CVS' weak share price, and it is unclear how much investors would reward that business as a standalone entity, especially on current year or next year's earnings. Put another way, we think CVS Health could generate substantial shareholder value by improving margins within Aetna over the next few years," Lutz wrote.